Takeda is relocating hundreds of jobs, a key Velcade patent was restored till 2022, 36 drugs were added to China's insurance drug list after huge…
AstraZeneca CEO Pascal Soriot is publicly keeping silent on last week’s report that he was bound for Teva. But not so, inside the company.
CAR-T and TCR therapies have seen a whirlwind few years. Is 2017 set to be the year we see a CAR-T therapy approved? On a mission to find out, we sat down with…
Amid plenty of CEO speculation, Teva got some good news Thursday on the respiratory front.
Merck & Co. nabbed tentative FDA approval for its Lantus copy, Lusduna, which would be the second follow-on challenger to the Sanofi blockbuster.
With the expanding definition of “health” in play, does the category warrant a separate show in a program like the Lions?
Purdue, which has been fending off lawsuits over pain drug OxyContin in the U.S., may have to face off against Canada’s federal government.
Puma reportedly set a price of $126,000 per year for its brand-new breast cancer drug Nerlynx—and analysts are hiking sales forecasts because of it.
Shire fought hard to stop it, but no dice: CSL has now launched its hereditary angioedema med Haegarda—and at a big discount, too.
Not only is Merck’s Keytruda still grabbing market share from Bristol-Myers Squibb archrival Opdivo, but it’s picked up the pace, too.
Johnson & Johnson has successfully fended off most Remicade biosimilar competition, and it has a three-pronged strategy to thank.
Price-fixing allegations against generics makers just keep piling up, with Mylan, Teva and other players targeted in yet another lawsuit.